Chiasma IncEquity-NMS: CHMA
Equity-NMS: CHMA
$3.76
NA
(3 Dec)
Loading Chart
1D
1W
3M
1Y
5Y
Previous close
$3.76
Open
$3.76
5Y
-6.63%
Market cap
0
Insights
CHMA price is below its 200 day moving average
CHMA PE is in the top end of its range over the past 2 years
In beta. Send feedback here.
Compare with other stock
Price
1D
PE
Market cap
About Chiasma Inc

Chiasma, Inc. is a biopharmaceutical company. The Company is engaged in developing and commercializing oral forms of therapies that are available only by injection. Using its Transient Permeability Enhancer (TPE) technology platform, the Company is developing oral therapies. The Company has completed a Phase III clinical trial of its TPE platform-based product candidate, oral octreotide capsules (trade named as MYCAPSSA) for the treatment of acromegaly, a condition that results in the body's production of excess growth hormone.

Octreotide is an analog of somatostatin, a natural inhibitor of growth hormone secretion. The Company is developing octreotide capsules as a liquid-filled solid gelatin capsule formulation, which is intended to be taken over twice a day. The Company's TPE technology enhances the absorption through the intestinal wall of drugs. The Company also focuses on developing CH2 for Orphan indication. .


FAQs

Can I buy Chiasma Inc shares in India?
How to buy Chiasma Inc shares in India?
What is the share price of Chiasma Inc?
What is the Market Capitalization of Chiasma Inc?
What is the PE ratio of Chiasma Inc?
Is Chiasma Inc a good stock to buy?
In which sector / industry does Chiasma Inc operate?